Ena Respiratory closed an AU$34 million (US$22.4 million) Series B to advance INNA‑051, a nasal spray candidate for symptomatic viral respiratory infections, into Phase II. Investors include the Gates Foundation and Flu Lab alongside existing backers Brandon Capital, Uniseed and Stoic Venture Capital. The Melbourne‑based company said funding will support regulatory and clinical development activities for INNA‑051 and expand manufacturing and trial capacity. The investor mix—public health funders plus venture capital—signals continued philanthropic and private interest in deployable, broad‑spectrum antivirals for outbreak preparedness.